Skip to main content
. 2017 Dec 8;2017(1):358–364. doi: 10.1182/asheducation-2017.1.358

Figure 2.

Figure 2.

The schema of S1608 is depicted. Patients with POD24 after bendamustine-rituximab induction therapy will be randomized to either the phosphatidylinositol 3-kinase inhibitor TG1202 plus obinutuzumab (Arm A), lenalidomide-obinutuzumab (Arm B), or R-CHOP (Arm C).